Watchlist: NVAXNVAX is now on my watchlist for tomorrow. I got a setup signal and with above average volume . Looking to enter if the stock can manage to close above the last candle highs with a stop-loss below and a price target above.Longby StockHunter88Published 7723
Novavax Printing a Clear Bull Flag | We've Seen This BeforeIn my previous idea, I showed how the NVAX chart had completed a textbook Wyckoff accumulation schematic, and the resulting big move upward into the "sign of strength" phase was almost exactly as predicted. As of today, we've just about completed a textbook Wyckoff "sign of strength" phase. The last time we saw this same style bull flag on the Novavax chart, the price quickly shot up more than 1,700% before consolidating and making another big move upward.Longby pridefulSeafow70205Published 221
NVAX - Novavax, Inc.Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.Longby Esmail_from_KuwaitPublished 2
NVAXBought this on 9th Sept at $12.52 Now 9.42% profit. Will it go further up?Longby Joekenstein7Published 3
NVAX, is prepping for a turnaround ERA. Massive Growth Prospect!NVAX surged an impressive 29.4% last trading day with significant volume. Net positive volume increased massively from 6.33M to 28.12M for a 344% increase. These extraordinary numbers should be telling of what's to come in the mid to long term. Buyers are back in the scene, positioning at the current price range in anticipation of growth prospect both in technical and fundamental aspect. On our monthly data, some big shifts are happening. On histogram, the stock recorded its third straight shifted lines -- these lines came out after 3.5 years of waiting. Similarly, a fresh bubble up volume re-appeared after a series of descend over the years. This is giving us a lowkey clue already of the intended direction. It is now sitting a 1.0 FIB level, this is beyond bargain / discount already. The stock is hovering around a 4-year longstanding strong support. Expect some upside price valuation to materialize in the next coming weeks. All these 'shifts' are conveying a turnaround prospect for NVAX. Spotted at 9.0 TAYOR. Safeguard capital always Longby JSALUpdated 101046
$NVAX incoming $44.32Novavax, incoming possible $44.32 target due to head and shoulders pattern and falling wedge. Longby trader06510Published 10
NVAX target $44.32 by September 2024NVAX inverse head and shoulders target of $44.32 by September 2024? Weekly projected chart coming off right shoulder with targets. Longby trader06510Published 6
NVAX falling wedge projection of $25.59Novovax falling wedge target projection of $25.59 based on projections using $3.81 in April 2024 and $23.86 from June 2024Longby trader06510Published 5
$NVAX incomingNASDAQ:NVAX incoming long projected falling wedge. Based on projected script Longby trader06510Published 117
NVAX listed on Nasdaq. I bought these shares at the very bottomNVAX listed on Nasdaq. I bought these shares at the very bottom. I made a take profit at the price of 16. Now we have a correction and I expect a drop to the price of 5.05 and there I will buy shares of this companyby TradeWave07Published 2
NVAX will make us happy soon.1) RSI 2 moving averages will cross each other soon. Purple one 38.14 and Green one 38.69. If purple one cut above green one it will be buy sign. I am waiting for buying next year because this is monthly chart. I hope RSI's 2 moving averages will cross each other. 36.91, 35.21 and 31.72 were very important support line in the past and it reversed from this level. 2) Momentum is reaching 0 line. If it is less than 0, it shows that down trend. If it is more than 0, it shows that upper trend. Of course NVAX decreased a lot but Momentum is trying to exceed 0 line up. If Momentum is reaching 0 line from minus, it means that down trend is losing its power and it will be reversal of trend. 3) DMI indicator has 3 moving averages inside of it. ADX is red one and it shows that trend's power not direction. If it is less than 20, it means that this is sideways market. It will be more than 20 in the future. Now it is 16.2284. If ADX is more than 20, it shows that this security has strong trend. It can be upper or down trend, we cannot know. We have to check out prices or Momentum indicator. 4) It is not certain but can work why not. Target Price = Minimum 168. Maximum 330. Because i calculated like that: (Highest level of prices + Lowest level of prices)/2 = Target Price ALL COMMENTS DO NOT İNCLUDE INVESTING ADVICE!by EmirhanhmcUpdated 282836
NVAX: Continuity of the upward trendOn NVAX we would have a continuity of the upward trend with regard to the configuration on the chart. We have the vwap indicator as well as the resistance line which have been broken with force.Longby PAZINI19Published 13
5-Year Opportunity to 20x Your Money in 400 Days?Novavax, Inc. (NVAX) has recently bounced off a 5-year support line, potentially paving the way for a bullish move that could yield a 2,000% profit. 🚀 - The RCI 3 line indicator shows a bullish crossing of the middle and long trend lines. - The RSI spiked above the moving average. - A rare bullish signal has appeared below the chart. The last time this happened was in December 2019, before a strong bull run. If history repeats itself, a profit of 20 times your money in 400 days is possible. What do you think?Longby ValerianKUpdated 2235
NVAX a buyNASDAQ:NVAX is a buy here. SLO STO reset daily and is higher on the 30-minute chart with a 7/21 EMA cross-over. Targets $18 and above. Longby allamerathletePublished 11
NVAX pushed to bottom of its channel LONGNVAX powered off its earnings and a news catalyst and is overdue now for a correction. While in an ascending channel NVAX is now at the bottom of the channel perhaps due to the general market moves this week. From here it can move up in the channel or breakdown and fall into a significant correction from the uptrend since May 10th. I am bullish on NVAX and have a prior perspective of an insider. I have realized profit six figures from my call options for January 2025 and have a large number remaining in the trade. At this juncture, I will watch for NVAX to move up in the channel and take a trade of shares and some call options for 15.00 expiring in June 2025 to take advantage of long term capital gains on the options. The FDA is currently reviewing some COVID vaccine data which is particularly relevant to NVAX. The volume profile has a shelf at 14.25 which will be my stop loss on the shares. The options will have a 20% stop loss. Considering the level from which NVAX has fallen over a period of some period there is great potential in my opinion. Longby AwesomeAvaniUpdated 2214
NVAX to $45 imoThis thing just ended its cycle of shorts, and made some partnership happen. no resistances for now. $20 will be easy, but with options, you can make some serious gains. January expiry isn't even that expensive Just be cautious always as it's $2bil market cap, unlike AMZN or MSFT for the trillions. NFA. Good luck PS. might wanna peek the dystopian pandemic treaty... there's a reason you haven't heard about it yet. simple google search will doLongby sully357Published 12
Sanofi Set to Take a 4.9% Stake in Novavax for $70 MillionShah Capital has announced the withdrawal of its campaign against the re-election of three directors on Novavax's board following the COVID-19 vaccine maker's licensing deal with Sanofi. The deal, signed on May 10, entails Sanofi taking a 4.9% stake in Novavax for $70 million at a substantial valuation, including an upfront cash payment of $500 million and future payments contingent on specific milestones and royalties. This move comes after Novavax ( NASDAQ:NVAX ) struggled to bring its protein-based vaccine to the market in a timely manner. Furthermore, the company has removed a warning notice from February last year, which cast doubt on its ability to continue operations, signaling increased stability after the deal with Sanofi. Shah Capital, which holds approximately 7.8% stake in Novavax ( NASDAQ:NVAX ),said that the Sanofi agreement represents a "long-awaited step in the right direction." Despite the withdrawal of its campaign, the fund continues to assert that Novavax ( NASDAQ:NVAX ) would benefit from the addition of a stockholder representative on its board. Novavax ( NASDAQ:NVAX ) has reaffirmed its commitment to driving long-term value for all shareholders and has welcomed the decision by Shah Capital to end its campaign, deeming it as the right choice for shareholders and the company. Moreover, Shah Capital remains vigilant, stating its belief that significant additional value remains to be unlocked at Novavax ( NASDAQ:NVAX ). Technical Outlook The Maryland-based biotech company's stock rose approximately 8.53% to $14.21 in premarket trading, marking an almost threefold increase in value this year. Novavax ( NASDAQ:NVAX ) stock has a Relative Strength Index (RSI) of 79.87 which is quite overbought with the asset trying to maintain the new Resistance Level reached by it. Additionally, as of April 30, the stock's short interest stood at 32% of publicly available shares, according to analytical Data firm LSEG data. Longby DEXWireNewsPublished 4
Its a new generation called COVIDGather around the camp fire and lets forgive healthcare and biotech this year... and the last. This year its different, I want to see the rotation in over valuing vaccine stocks again. Longby LeapTradesUpdated 556
Novavax Surge Over 130% On $1.4 Bln Covid Shot Deal with SanofiNovavax shares ( NASDAQ:NVAX ) surged over 130% after a $1.4 billion deal with Sanofi was announced to commercialize its Covid vaccine and develop a new combination shot for protecting against the flu and Covid. The biotech firm announced a licensing agreement with Sanofi to sell Novavax’s Covid vaccine worldwide, with Sanofi paying Novavax $500 million upfront and future payments up to $700 million based on other milestones, in addition to royalties. Sanofi will receive a sole license to develop and commercialize a combination flu and Covid vaccine containing Novavax’s Covid shot and Sanofi’s flu shot. Novavax ( NASDAQ:NVAX ) is also entitled to launch and sales milestones of up to $200 million for any vaccine developed by Sanofi as part of the deal. The company expects to launch a late-stage trial of its own combination vaccine targeting Covid and the flu and a stand-alone flu shot later this year. The licensing agreement will likely lift Novavax’s “going concern” warning issued last year, after the company said “substantial doubt exists” to continue operating. A significant uptick for Novavax ( NASDAQ:NVAX ) shares follows yearslong financial woes for the biotech firm. The company cut its 2024 sales forecast in its first-quarter review, decreasing projections from between $800 million and $1 billion to $400 million to $600 million. Novavax ( NASDAQ:NVAX ) also reported a first-quarter net loss of $148 million, compared with a net loss of $294 million during the same period last year. As part of the deal, Sanofi is also taking a less than 5% equity stake in Novavax, and Novavax ( NASDAQ:NVAX ) will receive royalty payments for future sales of its COVID-19 vaccine and the future combination COVID-19 and flu vaccine. The deal will allow Novavax to lift its “going concern” warning, which was issued in early 2023 over concerns that it may not be able to financially survive as demand for COVID-19 vaccines waned. Alongside the Sanofi deal, Novavax ( NASDAQ:NVAX ) also reported first-quarter results that missed analyst estimates. Novavax ( NASDAQ:NVAX ) reported revenue for the first quarter of $93.9 million, shy of the $101.3 million analysts expected, and posted a loss of $147.6 million, or $1.05 per share, wider than the loss of $127.4 million, or 90 cents per share, that analysts projected. For the full fiscal year, Novavax ( NASDAQ:NVAX ) lowered its projected revenue to $400 million to $600 million, down from the previous range of $800 million to $1 billion. However, the estimated $570 million the company expects to receive from Sanofi this year pushed its combined revenue and payments projections higher, to $970 million to $1.17 billion. Technical Outlook Novavax ( NASDAQ:NVAX ) is up 98% as of the time of writing, trading above the 200-day Moving Average (MA). The stock has a Relative Strength Index (RSI) of 86.66 which is clearly in an overbought territory. The daily price charts depict an upside or upward gap that occurred as a result of the impending deal. Longby DEXWireNewsPublished 115
nvax made the vaccineits not unthinkable this stock exploded and then collapsed. that being said i dont think this particular pop will last long, and thats why im scalping a lower high bullish to countertrend daily averages that should sell off after.Longby cerealmarketUpdated 0
Now what?Seems like 3.5 is a string demand area that pushes the price very hard to the upside. The last time was in Jan 2020. I don't think is going to explode above 30 but the next resistance is at 10. This is a high volatile stock, I bought calls exp 04/19 strike 5.5. If this breaks out will be massive.Longby ArturoLPublished 8
Unpopular opinion: new cycle for NOVAVAXNovavax is, besides a big pharma stock and one of the main previous providers of COV!D vaccines, a cyclical stock. It has been for 20 years, and I'm betting 2% of my portfolio it is going to be again. Despite the latest earnings, we are in the midst of the early part of the global liquidity cycle, which doesn't mean up-only, but Novavax is likely to be only getting started right now... Who else is going to sell the stock at this price besides perma-bears?! GM.by alexrigonPublished 224
Novavax Sees 2024 Sales Flat to Lower, Plummeting By 26.4%In a quest to reclaim lost ground and assert its presence in the competitive COVID-19 vaccine market, Novavax (NASDAQ: NASDAQ:NVAX ) charts a strategic course aimed at improving commercial performance and gaining market share from industry giants Pfizer (PFE.N) and Moderna (MRNA.O). Despite facing headwinds and a larger-than-expected fourth-quarter loss, Novavax ( NASDAQ:NVAX ) remains undeterred in its pursuit of market dominance. Chief Executive John Jacobs acknowledges the company's disappointing performance during the recent vaccination campaign, attributing it to delayed market entry and logistical challenges. However, Jacobs remains resolute in his commitment to enhancing Novavax's competitive positioning and expanding its footprint in the burgeoning vaccine landscape. A key focal point of Novavax's ( NASDAQ:NVAX ) strategy is the pursuit of pre-filled syringes, a format favored by consumers and healthcare providers alike for its convenience and ease of use. Jacobs emphasizes the importance of targeted sales efforts and broad retail availability to drive uptake and accelerate market penetration. Despite near-term revenue challenges, Novavax ( NASDAQ:NVAX ) remains optimistic about its long-term prospects, projecting revenue for 2024 in the range of $800 million to $1 billion. The company's commitment to cost containment and operational efficiency underscores its determination to navigate uncertainties and drive sustainable growth in the years ahead. Novavax's ( NASDAQ:NVAX ) journey has been marked by highs and lows, from soaring market valuations to regulatory hurdles and manufacturing setbacks. However, the company's resilience and adaptability position it well to overcome obstacles and emerge as a formidable player in the global fight against COVID-19. While challenges persist, including lingering doubts about the company's financial viability, Novavax remains focused on execution and delivering value to stakeholders. Jacobs's emphasis on operational improvements and leaner processes reflects a renewed commitment to efficiency and effectiveness in the commercial market. As Novavax ( NASDAQ:NVAX ) embarks on this pivotal phase of its journey, investors and industry observers await eagerly to witness the company's ability to translate strategy into tangible results. With determination, perseverance, and a renewed sense of purpose, Novavax ( NASDAQ:NVAX ) seeks to redefine its narrative and carve out a prominent place in the annals of vaccine innovation.by DEXWireNewsPublished 5